Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However. their use has been restricted in patients with preexisting autoimmune diseases due to concerns about increased risk of immune-related adverse events (irAEs). Case presentation We present a case of a patient with stage IV lung adenocarcinoma and a history of complement-mediated autoim... https://herbsdailyes.shop/product-category/glandulars/